The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer
Open accessAbstract
Checkpoint inhibitors have demonstrated efficacy in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). However, the majority of patients do not benefit from these agents. To improve the efficacy of checkpoint inhibitors, intratumoral (i.t.) injection with innate immune activators, TLR7 and TLR9 agonists, were tested along with programmed death-1 receptor (PD-1) blockade. The combination therapy suppressed tumor growth at the primary injected and distant sites in human papillomavirus-negative (HPV-negative) SCC7 and MOC1, and HPV-positive MEER syngeneic mouse models. Abscopal effects and suppression of secondary challenged tumor suggest that local treatment with TLR agonists in combination with anti-PD-1 provided systemic adaptive immunity. I.t. treatment with a TLR7 agonist increased the ratio of M1 to M2 tumor-associated macrophages (TAMs) and promoted the infiltration of tumor-specific IFNγ-producing CD8+ T cells. Anti-PD-1 treatment increased T cell receptor (TCR) clonality of CD8+ T cells in tumors and spleens of treated mice. Collectively, these experiments demonstrate that combination therapy with i.t. delivery of TLR agonists and PD-1 blockade activates TAMs and induces tumor-specific adaptive immune responses, leading to suppression of primary tumor growth and prevention of metastasis in HNSCC models.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003
Microenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 1×
“Local and systemic clonal expansion of CD8 + T cells positively correlates with clinical outcomes and immune-related adverse effects after cancer immunotherapy (55–59).”
BackgroundThe chemokine system in diverse forms of macrophage activation and polarization
MANTOVANI, A., SICA, A., SOZZANI, S., ALLAVENA, P., VECCHI, A., & LOCATI, M. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.09.015 · Cited by 6,534
Macrophage activation and polarization: nomenclature and experimental guidelines
Murray, P. J., Allen, J. E., Biswas, S. K., Fisher, E. A., Gilroy, D. W., Goerdt, S., Gordon, S., Hamilton, J. A., Ivashkiv, L. B., Lawrence, T., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.008 · Cited by 6,337
Macrophage plasticity and polarization: in vivo veritas
Sica, A., & Mantovani, A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59643 · Cited by 6,335
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Protective and pathogenic functions of macrophage subsets
Murray, P. J., & Wynn, T. A. (2011) · Nature Reviews Immunology · doi:10.1038/nri3073 · Cited by 5,269
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602252 · Cited by 5,101
The M1 and M2 paradigm of macrophage activation: Time for reassessment
Martinez, F. O., & Gordon, S. (2014) · F1000Prime Reports · doi:10.12703/p6-13 · Cited by 4,689
Innate and adaptive immune cells in the tumor microenvironment
Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148
Tumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089
Fakhry, C., Westra, W. H., Li, S., Cmelak, A., Ridge, J. A., Pinto, H., Forastiere, A., & Gillison, M. L. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn011 · Cited by 2,779
Case–Control Study of Human Papillomavirus and Oropharyngeal Cancer
D'Souza, G., Kreimer, A. R., Viscidi, R., Pawlita, M., Fakhry, C., Koch, W. M., Westra, W. H., & Gillison, M. L. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065497 · Cited by 2,692
The molecular biology of head and neck cancer
Leemans, C. R., Braakhuis, B. J. M., & Brakenhoff, R. H. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2982 · Cited by 2,524
Small anti-viral compounds activate immune cells via the TLR7 MyD88–dependent signaling pathway
Hemmi, H., Kaisho, T., Takeuchi, O., Sato, S., Sanjo, H., Hoshino, K., Horiuchi, T., Tomizawa, H., Takeda, K., & Akira, S. (2002) · Nature Immunology · doi:10.1038/ni758 · Cited by 2,522
Mathematical Theory of Communication
(2009) · Encyclopedia of Communication Theory · doi:10.4135/9781412959384.n229 · Cited by 2,492
Sato, E., Olson, S. H., Ahn, J., Bundy, B., Nishikawa, H., Qian, F., Jungbluth, A. A., Frosina, D., Gnjatic, S., Ambrosone, C., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509182102 · Cited by 2,372
Mathematical Theory of Communication
(2009) · Encyclopedia of Neuroscience · doi:10.1007/978-3-540-29678-2_3338 · Cited by 2,297
From Monocytes to M1/M2 Macrophages: Phenotypical vs. Functional Differentiation
Italiani, P., & Boraschi, D. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00514 · Cited by 2,067 · cited 1×
“As opposed to M1-like macrophages, activated M2-like macrophages promote tumor initiation, progression, and metastasis (24–26).”
BackgroundMacrophages and Therapeutic Resistance in Cancer
Ruffell, B., & Coussens, L. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.02.015 · Cited by 1,474 · cited 1×
“Collectively, these experiments demonstrate that combination therapy with i.t. delivery of TLR agonists and PD-1 blockade activates TAMs and induces tumor-specific adaptive immune responses, leading to suppression of primary tumor growth and prevention of metastasis in HNSCC models. outcome (22).”
BackgroundCooperation of Toll-like receptor signals in innate immune defence
Trinchieri, G., & Sher, A. (2007) · Nature Reviews Immunology · doi:10.1038/nri2038 · Cited by 1,364
Type I interferons in anticancer immunity
Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M. J., & Kroemer, G. (2015) · Nature Reviews Immunology · doi:10.1038/nri3845 · Cited by 1,305
PI3Kγ is a molecular switch that controls immune suppression
Kaneda, M. M., Messer, K. S., Ralainirina, N., Li, H., Leem, C. J., Gorjestani, S., Woo, G., Nguyen, A. V., Figueiredo, C. C., Foubert, P., et al. (2016) · Nature · doi:10.1038/nature19834 · Cited by 1,173
Self-citationSindrilaru, A., Peters, T., Wieschalka, S., Baican, C., Baican, A., Peter, H., Hainzl, A., Schatz, S., Qi, Y., Schlecht, A., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44490 · Cited by 1,100 · cited 1×
“Classically activated M1-like macrophages are considered immunostimulatory and inhibit tumor growth, associated with the induction of high levels of proinflammatory cytokines and increased levels of oxygen and nitrogen radicals (68–70).”
BackgroundNovel Markers to Delineate Murine M1 and M2 Macrophages
Jablonski, K. A., Amici, S. A., Webb, L. M., Ruiz-Rosado, J. D. D., Popovich, P. G., Partida-Sanchez, S., & Guerau-de-Arellano, M. (2015) · PLOS ONE · doi:10.1371/journal.pone.0145342 · Cited by 978
Chow, L. Q. M., Haddad, R., Gupta, S., Mahipal, A., Mehra, R., Tahara, M., Berger, R., Eder, J. P., Burtness, B., Lee, S.-H., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.1478 · Cited by 857
Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients
Baitsch, L., Baumgaertner, P., Devêvre, E., Raghav, S. K., Legat, A., Barba, L., Wieckowski, S., Bouzourene, H., Deplancke, B., Romero, P., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46102 · Cited by 845
Nakano, O., Sato, M., Naito, Y., Suzuki, K., Orikasa, S., Aizawa, M., Suzuki, Y., Shintaku, I., Nagura, H., & Ohtani, H. (2001) · PubMed · Cited by 639
Zhang, M., He, Y., Sun, X., Li, Q., Wang, W., Zhao, A., & Di, W. (2014) · Journal of Ovarian Research · doi:10.1186/1757-2215-7-19 · Cited by 528
Sharma, P., Shen, Y., Wen, S., Yamada, S., Jungbluth, A. A., Gnjatic, S., Bajorin, D. F., Reuter, V. E., Herr, H., Old, L. J., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611618104 · Cited by 526
The determinants of tumour immunogenicity
Blankenstein, T., Coulie, P. G., Gilboa, E., & Jaffee, E. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3246 · Cited by 441
Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer
Ward, M. J., Thirdborough, S. M., Mellows, T., Riley, C., Harris, S., Suchak, K., Webb, A., Hampton, C., Patel, N. N., Randall, C. J., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2013.639 · Cited by 391
Improved Survival with T Cell Clonotype Stability After Anti–CTLA-4 Treatment in Cancer Patients
Cha, E., Klinger, M., Hou, Y., Cummings, C., Ribas, A., Faham, M., & Fong, L. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008211 · Cited by 383
Triggering TLR signaling in vaccination
van Duin, D., Medzhitov, R., & Shaw, A. C. (2006) · Trends in Immunology · doi:10.1016/j.it.2005.11.005 · Cited by 364
Lechner, M. G., Karimi, S. S., Barry-Holson, K., Angell, T. E., Murphy, K. A., Church, C. H., Ohlfest, J. R., Hu, P., & Epstein, A. L. (2013) · Journal of Immunotherapy · doi:10.1097/01.cji.0000436722.46675.4a · Cited by 350
Macrophage PI3Kγ Drives Pancreatic Ductal Adenocarcinoma Progression
Kaneda, M. M., Cappello, P., Nguyen, A. V., Ralainirina, N., Hardamon, C. R., Foubert, P., Schmid, M. C., Sun, P., Mose, E., Bouvet, M., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1346 · Cited by 326
Self-citationOhri, C. M., Shikotra, A., Green, R. H., Waller, D. A., & Bradding, P. (2009) · European Respiratory Journal · doi:10.1183/09031936.00065708 · Cited by 296
Zamai, L., Ponti, C., Mirandola, P., Gobbi, G., Papa, S., Galeotti, L., Cocco, L., & Vitale, M. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.7.4011 · Cited by 292
Alternatively activated macrophages in infection and autoimmunity
Fairweather, D., & Cihakova, D. (2009) · Journal of Autoimmunity · doi:10.1016/j.jaut.2009.09.012 · Cited by 290
Postow, M. A., Manuel, M., Wong, P., Yuan, J., Dong, Z., Liu, C., Perez, S., Tanneau, I., Noel, M., Courtier, A., et al. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0070-4 · Cited by 232
Wang, S., Campos, J., Gallotta, M., Gong, M., Crain, C., Naik, E., Coffman, R. L., & Guiducci, C. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1608555113 · Cited by 231
Self-citationSubudhi, S. K., Aparicio, A., Gao, J., Zurita, A. J., Araujo, J. C., Logothetis, C. J., Tahir, S. A., Korivi, B. R., Slack, R. S., Vence, L., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1611421113 · Cited by 226
ERK1/2 Regulation of CD44 Modulates Oral Cancer Aggressiveness
Judd, N. P., Winkler, A. E., Murillo-Sauca, O., Brotman, J. J., Law, J. H., Lewis, J. S., Dunn, G. P., Bui, J. D., Sunwoo, J. B., & Uppaluri, R. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1831 · Cited by 221
Davis, R. J., Moore, E. C., Clavijo, P. E., Friedman, J., Cash, H., Chen, Z., Silvin, C., Van Waes, C., & Allen, C. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2534 · Cited by 213
Through the Jungle of Biological Diversity
Ricotta, C. (2005) · Acta Biotheoretica · doi:10.1007/s10441-005-7001-6 · Cited by 207
The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system
Engel, A. L., Holt, G. E., & Lu, H. (2011) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.11.5 · Cited by 205
Prins, R. M., Craft, N., Bruhn, K. W., Khan-Farooqi, H., Koya, R. C., Stripecke, R., Miller, J. F., & Liau, L. M. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.1.157 · Cited by 203
Whitmore, M. M., DeVeer, M. J., Edling, A., Oates, R. K., Simons, B., Lindner, D., & Williams, B. R. G. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0063 · Cited by 183
VTX-2337 Is a Novel TLR8 Agonist That Activates NK Cells and Augments ADCC
Lu, H., Dietsch, G. N., Matthews, M.-A. H., Yang, Y., Ghanekar, S., Inokuma, M., Suni, M., Maino, V. C., Henderson, K. E., Howbert, J. J., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1625 · Cited by 176
Tracking of intertissue migration reveals the origins of tumor-infiltrating monocytes
Shand, F. H. W., Ueha, S., Otsuji, M., Koid, S. S., Shichino, S., Tsukui, T., Kosugi-Kanaya, M., Abe, J., Tomura, M., Ziogas, J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1402914111 · Cited by 175
Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy
Iribarren, K., Bloy, N., Buqué, A., Cremer, I., Eggermont, A. M. M., Fridman, W. H., Fucikova, J. P., Galon, J., Špíšek, R., Zitvogel, L., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1088631 · Cited by 142
Current Clinical Trials Testing Combinations of Immunotherapy and Radiation
Crittenden, M. R., Kohrt, H. E. K., Levy, R., Jones, J. C., Camphausen, K. A., Dicker, A. P., Demaria, S., & Formenti, S. C. (2014) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2014.07.003 · Cited by 135
Methods for diversity and overlap analysis in T-cell receptor populations
Rempała, G. A., & Seweryn, M. T. (2012) · Journal of Mathematical Biology · doi:10.1007/s00285-012-0589-7 · Cited by 125
Harnessing NK Cell Memory for Cancer Immunotherapy
Fehniger, T. A., & Cooper, M. A. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.09.005 · Cited by 111
Synthesis and Immunological Characterization of Toll-Like Receptor 7 Agonistic Conjugates
Chan, M., Hayashi, T., Kuy, C. S., Gray, C. S., Wu, C. C. N., Corr, M., Wrasidlo, W., Cottam, H. B., & Carson, D. A. (2009) · Bioconjugate Chemistry · doi:10.1021/bc900054q · Cited by 107
Self-citationBourquin, C., Hotz, C., Noerenberg, D., Voelkl, A., Heidegger, S. M., Roetzer, L. C., Storch, B., Sandholzer, N., Wurzenberger, C., Anz, D., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3903 · Cited by 86
Immunity in Head and Neck Cancer
Schoenfeld, J. D. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0205 · Cited by 76
Immunotherapy in head and neck cancer: aiming at EXTREME precision
Szturz, P., & Vermorken, J. B. (2017) · BMC Medicine · doi:10.1186/s12916-017-0879-4 · Cited by 75
Fidock, M. D., Souberbielle, B. E., Laxton, C. D., Rawal, J. K., Delpuech-Adams, O. E., Corey, T., Colman, P., Kumar, V., Cheng, J. B., Wright, K., et al. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.60 · Cited by 71
Whang, S. N., Filippova, M., & Duerksen-Hughes, P. J. (2015) · Viruses · doi:10.3390/v7092860 · Cited by 62
Negative regulation of TLR9-mediated IFN-α induction by a small-molecule, synthetic TLR7 ligand
Marshall, J. D., Heeke, D., Gesner, M. L., Livingston, B. D., & Nest, G. V. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.0906575 · Cited by 56
Echarri, M. J., Martín, A. L., & Hitt, R. (2016) · Cancers · doi:10.3390/cancers8030027 · Cited by 53
Yoshida, R., Yoshioka, T., Yamane, S., Matsutani, T., Toyosaki‐Maeda, T., Tsuruta, Y., & Suzuki, R. (2000) · Immunogenetics · doi:10.1007/s002510000248 · Cited by 51
Self-citationTamura, K., Hazama, S., Yamaguchi, R., Imoto, S., Takenouchi, H., Inoue, Y., Kanekiyo, S., Shindo, Y., Miyano, S., Nakamura, Y., et al. (2016) · Oncology Letters · doi:10.3892/ol.2016.4465 · Cited by 43
Kauppila, J. H., Korvala, J., Siirilä, K., Manni, M., Mäkinen, L. K., Hagström, J., Atula, T. S., Haglund, C. H., Selander, K. S., Saarnio, J., et al. (2014) · Journal of Oral Pathology and Medicine · doi:10.1111/jop.12272 · Cited by 33
Kotrashetti, V., Nayak, R. S., Bhat, K. G., Hosmani, J., & Somannavar, P. (2013) · Biotechnic & Histochemistry · doi:10.3109/10520295.2013.785592 · Cited by 31
Immunomodulatory approaches for prevention and treatment of infectious diseases
Nijnik, A. (2013) · Current Opinion in Microbiology · doi:10.1016/j.mib.2013.06.011 · Cited by 29
Hayashi, T., Chan, M. D., Norton, J. T., Wu, C. C. N., Yao, S., Cottam, H. B., Tawatao, R. I., Corr, M., Carson, D. A., & Daniels, G. A. (2010) · Melanoma Research · doi:10.1097/cmr.0b013e328340ce6c · Cited by 26
Self-citationAlexander, G. S., Palmer, J. D., Tuluc, M., Lin, J., Dicker, A. P., Bar‐Ad, V., Harshyne, L. A., Louie, J., Shaw, C. M., Hooper, D. C., et al. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0328-4 · Cited by 26
Wu, C. C. N., Crain, B., Yao, S., Sabet, M., Lao, F. S., Tawatao, R. I., Chan, M., Smee, D. F., Julander, J. G., Cottam, H. B., et al. (2013) · Journal of Innate Immunity · doi:10.1159/000355217 · Cited by 22
Self-citation
Cited by
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,409
Toll-Like Receptor Signaling and Its Role in Cell-Mediated Immunity
Duan, T., Du, Y., Xing, C., Wang, H. Y., & Wang, R.-F. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.812774 · Cited by 972
Choo, Y. W., Kang, M., Kim, H. Y., Han, J., Kang, S., Lee, J.-R., Jeong, G.-J., Kwon, S. P., Song, S. Y., Go, S., et al. (2018) · ACS Nano · doi:10.1021/acsnano.8b02446 · Cited by 465
Neophytou, C. M., Panagi, M., Stylianopoulos, T., & Papageorgis, P. (2021) · Cancers · doi:10.3390/cancers13092053 · Cited by 456
Xia, L., Liu, Y., & Wang, Y. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-io-s1-s05 · Cited by 394
Metadata
- Authors
- Sato-Kaneko, F., Yao, S., Ahmadi, A., Zhang, S. S., Hosoya, T., Kaneda, M. M., Varner, J. A., Pu, M., Messer, K. S., Guiducci, C., Coffman, R. L., Kitaura, K., Matsutani, T., Suzuki, R., Carson, D. A., Hayashi, T., & Cohen, E. E. W.
- Venue
- JCI Insight
- Published
- 2017-09-21
- Volume
- 2
- Issue
- 18
- ISSN
- 2379-3708 (ISSN-L)
- OpenAlex
- W2755073646
- Cited by
- 280
- References
- 71
- FWCI
- 11.31
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.